About us

Vironova Medical AB was founded in 2015 as a spin-out from Vironova AB by Mr Mohammed Homman and the late Prof. Jan Bergman. Vironova Medical is commercializing a patented chemical process technology for thionation named Jan Bergman Reagent, “JBR” after its inventor. We are using JBR in the development of pharmaceuticals including antiviral compounds, that make up part of our portfolio and compound library. 

Board of directors

Mohammed Homman

Co-founder and Chairman 

Alf Sollevi

Board Member

Ulf Säther

Board Member

Mats Persson

Board Member

Maria Homman


Key Management

Eva O’Keeffe


Mohammed Homman

Co-founder and Chairman

Mats Henriksson

Marketing Director

Jingyi Zhang

Investor Relations

Robert Almqvist

Finance and Accounting Manager 

Dmitry Antonov

Principal Scientist

Prof. Jan Bergman

Co-founder of Vironova Medical AB

1941 – 2021

The former CEO and co-founder of Vironova Medical, Prof. Jan Bergman, sadly pasted away in December 2021 at an age of 80 years. He was one of the two founders of Vironova Medical and instrumental to the company.

His research has laid the foundation of Vironova Medical, and all his work at his retirement from the Karolinska Institute was injected into the company. He was active at both KTH, The Royal Institute of Technology, and The Karolinska Institute as Professor for more than 40 years where he ran the Unit of Organic Chemistry in the Department of Biosciences at Novum. His work during this period resulted in +300 scientific publications and 25 patents. The most significant invention for our company is the Jan Bergman thionation reagent, JBR. You can find a link to the full tribute by the renowned chemist Emeritus Professor John Joule at The School of Chemistry, The University of Manchester here.

Link to A Tribute to Prof. Jan Bergman

Most relevant publications

  • Bergman, J. ‘Comparison of two reagents for thionations’ Synthesis 2018, 50, 2323.Zhang, Q.; Bergman, J.; Wiman, K. G.; Bykov, V. J. N. ‘Role of thiol reactivity for targeting mutant p53’ Cell Chem. Biol. 2018, 1219.
  • Bergman, J.; Pettersson, B; Hasimbegovic, V.; Svensson, P. H. ‘Thionations using a P4S10-pyridine complex in solvents such as acetonitrile and dimethyl sulfone’ J. Org. Chem. 2011, 76, 1546.
  • Kingi, N.; Bergman, J. ‘Thionation of tryptanthrin, rutaecarpine and related molecules with a reagent prepared from P4S10 and pyridine’ J. Org. Chem. 2016, 81, 7711.
  • Bergman, J.; Bergman, S. ‘Synthesis of rutaecarpine and related indole alkaloids’ Heterocycles 1981, 16, 347.
  • Harmenberg, J.; Wahren, B.; Bergman, J.; Aakerfeldt, S.; Lundblad, L. ‘Antiherpesvirus activity and mechanism of action of indolo[2,3-b]qunoxaline and analogs’ Antimicrob. Agents Chemother. 1988, 32, 1720.
  • Bergman, J.; Stalhandski, C. ‘Transformation of isatin with P4S10 to pentathiepino[6,7-b]indole in one step’  Tetrahedron Lett. 1994, 35, 5279.
  • Sehlstedt, U.; Aich, P.; Bergman, J.; Valiberg, H.; Norden, B.; Gräslund, A. ‘Interactions of the antiviral qunoxaline deritivative 9-OH-B220 (2,3-dimethyl-6-(dimethylaminoethyl)-9-hydroxy-6H-indolo[2,3-b]quinoxaline) with duplex and triplex forms of synthetic DNA and RNA’ J. Mol. Biol. 1998, 278, 31.
  • Homman, M.; Kingi, N.; Bergman, J.; Berg, R. ‘Methanethione compounds having antiviral activity’ In: Vironova AB Swed. 2015.
  • Janosik, T.; Bergman, J.; Stensland, B.; Stalhandske, C. ‘Thionation of bisindole derivatives with P4S10 or elemental sulfur’ J. Chem. Soc., Perkin Trans. 1 2002, 330.